1. Home
  2. SNT vs INKT Comparison

SNT vs INKT Comparison

Compare SNT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$1.56

Market Cap

64.6M

ML Signal

HOLD

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

BUY

Current Price

$11.41

Market Cap

59.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
SNT
INKT
Founded
1965
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
59.4M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
SNT
INKT
Price
$1.56
$11.41
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
6.9K
9.7K
Earning Date
04-23-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.59
$8.48
52 Week High
$5.34
$16.80

Technical Indicators

Market Signals
Indicator
SNT
INKT
Relative Strength Index (RSI) 43.94 56.23
Support Level $1.59 $10.79
Resistance Level $1.89 $12.04
Average True Range (ATR) 0.07 0.55
MACD -0.00 0.05
Stochastic Oscillator 33.65 61.50

Price Performance

Historical Comparison
SNT
INKT

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: